We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBO
226
PUT
DELISTED
Albireo Pharma Inc
ALBO
$24 ﹤0.01%
6
– –
RXII
227
CALL
DELISTED
GALENA BIOPHARMA INC COM
RXII
$21 ﹤0.01%
+139
New +$21
CVM icon
228
CEL-SCI Corp
CVM
$20.6M
$8 ﹤0.01%
17
– –
AAPL icon
229
CALL
Apple
AAPL
$5.03T
– –
-1,200
Closed -$3.02K
AAPL icon
230
PUT
Apple
AAPL
$5.03T
– –
-1,200
Closed -$3.02K
ABUS icon
231
CALL
Arbutus Biopharma
ABUS
$863M
– –
-883
Closed -$1.87K
ABUS icon
232
PUT
Arbutus Biopharma
ABUS
$863M
– –
-1,212
Closed -$2.56K
ACHC icon
233
CALL
Acadia Healthcare
ACHC
$2.63B
– –
-28,073
Closed -$69.5K
ACHC icon
234
Acadia Healthcare
ACHC
$2.63B
– –
-663,324
Closed -$16.4K
ACHC icon
235
PUT
Acadia Healthcare
ACHC
$2.63B
– –
-1,022
Closed -$2.53K
ALNY icon
236
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-773
Closed -$6.04K
ALTO icon
237
Alto Ingredients
ALTO
$343M
– –
-22,900
Closed -$320
ALTO icon
238
PUT
Alto Ingredients
ALTO
$343M
– –
-317
Closed -$443
AMGN icon
239
PUT
Amgen
AMGN
$213B
– –
-549
Closed -$7.71K
ARCT icon
240
CALL
Arcturus Therapeutics
ARCT
$165M
– –
-83
Closed -$900
ARCT icon
241
PUT
Arcturus Therapeutics
ARCT
$165M
– –
-523
Closed -$5.65K
ARWR icon
242
Arrowhead Research
ARWR
$12.2B
– –
-30,513
Closed -$451
ARWR icon
243
PUT
Arrowhead Research
ARWR
$12.2B
– –
-1,000
Closed -$1.48K
BCLI
244
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-53,884
Closed -$3.32K
BLUE
245
DELISTED
bluebird bio
BLUE
– –
-1,897
Closed -$1.27M
CGEN icon
246
Compugen
CGEN
$215M
– –
-3,400
Closed -$29
FOCL
247
CALL
EDAP TMS S.A.
FOCL
$231M
– –
-423
Closed -$55
FOCL
248
EDAP TMS S.A.
FOCL
$231M
– –
-14,524
Closed -$26K
ENTA icon
249
CALL
Enanta Pharmaceuticals
ENTA
$368M
– –
-130
Closed -$514
EXAS
250
DELISTED
Exact Sciences
EXAS
– –
-21,952
Closed -$534K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.